Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
ADRB1 and ADRB2 antihypertensive target perturbations associated with increased clear cell renal cell carcinoma risk
Genetic markers linked to blood pressure drugs raise kidney cancer risk
This meta-analysis of Mendelian randomization and colocalization analyses found that genetic perturbations equivalent to antihypertensive dr…
Genetic data suggests certain blood pressure targets may increase clear cell renal cell carcinoma risk, a finding that warrants attention fo…
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.
CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
New Test Finds Hidden TB in Kidney Tissue
A retrospective cohort study of 86 patients with surgically resected renal tissue found CFP10 immunohistochemical staining had 91.8% sensiti…
A new kidney test spots hidden tuberculosis by finding a specific protein that standard methods often miss, helping doctors catch the infect…
Research across Urologic Neoplasms
Related studies from across the Urologic Neoplasms family.
Percutaneous thermal ablation shows higher local recurrence than robot-assisted partial nephrectomy for localized renal cell carcinoma
Meta-analysis shows higher local recurrence risk with thermal ablation for kidney cancer
This systematic review and meta-analysis of 2,516 patients with localized renal cell carcinoma compared percutaneous thermal ablation to rob…
A large analysis of kidney cancer treatments found thermal ablation had higher local recurrence rates than partial nephrectomy, though overa…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.
Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
Active surveillance vs ablation for small kidney tumors: what works?
This systematic review and meta-analysis evaluates active surveillance (AS) versus ablative therapy (AT) for patients with small renal masse…
For small kidney tumors, ablation may boost survival, but cancer-specific death risk is similarly low with either approach.
Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
Small kidney tumors may not need surgery right away
This prospective multi-institutional study evaluated active surveillance in patients aged over 50 years with asymptomatic, unilateral small …
Many small kidney tumors stay harmless for years, meaning patients might avoid surgery and its risks without putting their health in danger.
Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients
Old cancer drugs failed, but one new drug saves high-risk kidney patients today
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients
Open-source CT scans aim to boost kidney cancer AI research
This cohort study involved 101 patients with renal cell carcinoma (RCC) and analyzed 142 annotated CT scans.
Researchers release 142 annotated CT scans from 101 kidney cancer patients to accelerate AI development.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Targeted therapy versus non-targeted therapy in renal cell carcinoma patients
Real-world study in Taiwan shows targeted therapy offers similar life expectancy for advanced kidney cancer compared to non-targeted therapy
This real-world cohort study analyzed 14,131 renal cell carcinoma cases in Taiwan from 1998 to 2016.
In Taiwan, targeted therapy for advanced kidney cancer offers similar life expectancy to non-targeted therapy, with both groups living aroun…